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Abstract
Background: The N-Nitrosomethylurea breast cancer model induced in rats is used for the study
of carcinogenesis in mammary cancer, prostate, pancreas, etc. This model is very similar to human
neoplastic disease.
Methods: The present experimental study was designed to assess whether metoclopramide
administration has any effect on development of MNU-induced tumours, and evaluate the
treatment of goserelin acetate on PRL, TNF alpha and NO expression. NMU was administered to
female Wistar rats on 2 occasions (5 mg/100 g body w/rat). PRL and TNF alpha were performed
by immune-assay. Nitric Oxide by semi automated-assay and ploidy analyses by flow cytometry.
Results: The administration of metoclopramide made the induction time shorter and increased
the incidence and average of tumours per rat. Tumours development was inhibited by a goserelin
chronic administration. The ploidy of adenocarcinoma was polyploid-aneuploid type (average S =
60%). It was higher basal PRL plasma levels in rats with NMU induced tumours than in basal
controls without tumour (p < 0.001). The goserelin "in bolus" administration showed maximal
inhibition of plasma PRL at 90 min. Plasmatic TNF alpha expression was inhibited at 60 min and also
remained inhibited in tissue homogenate post chronic treatment (P < 0.0125). Plasmatic NO
expression is higher in rats with induced tumours than healthy controls (P < 0.001). In tissue
homogenate NO values were inhibited at 90 min (P < 0.01), as well during chronically goserelin
treatment (P < 0.005).
Conclusion: The increase of blood PRL levels in NMU-induced rats may be an indicator of a poor
prognosis of mammary cancer evolution. The metoclopramide administration accelerates tumour
growth. However goserelin administration achieves regression in tumour development associated
to inhibition PRL, TNF alpha and NO expression.
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Background
N-nitroso-N-methylurea (NMU) is an effective chemical
carcinogen for the induction of mammary carcinoma in
rats and a very good model for human mammary carcino-
mas [1-6]. Prolactin (PRL) is a mitogenic hormone similar
to growth factors and rat mammary tumour express PRL
messenger RNA and acts as a local growth factor that stim-
ulates proliferation of mammary tumours [7]. The pres-
ence of specific receptors for PRL has been demonstrated
and they belong to the cytokine family of receptors [8-10].
PRL may act as a positive growth factor in mammary
tumour development and increase the proliferation of
breast cancer cells in rats [7].
Metoclopramide (C14H22ClN3O2), their IUPAC name: 4-
amino-5-chloro-N-(2-diethylamino)ethyl-2-methoxy-
benzamide is a potent dopamine receptor antagonist used
for its antiemetic effect and by inhibiting the action of PRL
inhibiting hormone and has sometimes been used to
stimulate lactation. It thus may induce hyperprolactine-
mia in rats.
The agonistic analogue of gonadotrophin-releasing hor-
mone (LH-RH) is known to suppress ovarian function
and plasma prolactin levels and its antitumour activity
has been evaluated extensively [11].
In chemical carcinogenesis, internal cytokines, such as
interleukin (IL) 1α and tumour necrosis alpha (TNFα)
contribute to tumour progression. However it has been
suggested that TNF on tumour vasculature has a direct
anti-tumour mechanism [12-14]. Indeed estradiol has
inhibitory effects on IL 1α and TNFα mRNA and their pro-
teins expression [15].
Inducible nitric oxide synthase (iNOS) and nitric oxide
(NO) are implicated in tumour pathology and, it is well
known that TNFα induces iNOS and NO release. While
low concentrations of NO alter transcription factor and
act as an antioxidant factor, high concentrations of NO
can damage DNA and proteins. Moreover NO-induced
alteration in cellular function can lead to cell death or
stimulation of growth, and stimulate tumour growth by
promoting angiogenic and invasive capacities [16-19].
The aim of the study was to assess the effect of metoclo-
pramide on tumour development of NMU-induced
tumours in Wistar rats, and at the same time to study acute
and chronic administration of (LH-RH analogue) gosere-
lin on PRL, TNFα and NO expression in this experimental
model.
Methods
Animals
Wistar rats were used for all the experiments and were
obtained at 45 days of age. Animals were housed 2/cage in
a room illuminated for 12 h each day at a temperature of
25°C. The animals had free access to Purina laboratory
chow and drinking water. All the experiments in this study
were performed in compliance with the Royal Decree
223/1988 of March (BOE 8 18) and the Ministerial Order
of 13 October 1989 (BOE 8) regarding protection of the
experimental animals, as well as with the European Coun-
cil Directive of 24 November 1986 (86/609/EEC).
Chemicals
Crystalline NMU (Sigma, No. N1517) was dissolved in
0.85% NaCl solution and acidified (acetic acid) at 5.0 pH.
The concentration was then adjusted to 5 mg/100 g body
wt/rat. Heparin-treated blood (0.2 ml) was obtained by
cardiac puncture from rats lightly anesthetized with ether.
Tumour detection
Animals were palpated for detection of mammary
tumours initialling after injection of NMU and the ani-
mals were examined by palpation for tumour masses
thrice weekly post administration of carcinogen. Tumour
sizes were measured with a calliper and their growth and
histological parameters were tested.
Histology
The diagnoses of mammary gland cancer were made by
histological examination of paraffin sections stained with
haematoxylin/eosin in all tumours. Autopsy was per-
formed when the neoplasms were large. A nodule of
mammary cancer is designated an active tumour, the
number of active tumours is expressed per rat with mam-
mary cancer.
Preparation of tumour fraction and blood samples
The tumour samples were prepared in the following man-
ner: after sacrifice of the animals by decapitation the
tumours were removed immediately. All further steps in
the preparation were performed at 0–4°C. After being
washed in ice-cold PBS buffer (pH 7.4) the tumours were
homogenized in this buffer (10 ml/5 g of wet tumour).
The homogenate was isolated by centrifugation for 30
min at 9000 × g and the supernatant were stored in aliq-
uots at -80°C until used in each of the corresponding
assays.
Measurement of prolactin, TNF α and NO concentration 
in plasma and mammary tumour homogenate
Tumour homogenate and plasma were analyzed for prol-
actin concentration using a commercially available ELISA
kit (PRL, kit ELISA, Amersham Pharmacia Biotech, Barce-
lona, Spain). The basal level of rat plasma was in accordJournal of Carcinogenesis 2007, 6:18 http://www.carcinogenesis.com/content/6/1/18
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to that indicated and obtained using standard rat plasma
provided by the ELISA kit and indicating that rat stress was
avoided, as confirmed by the variability of the plasma
blood levels in controls.
For TNF α concentration was using a commercially avail-
able kit: (Factor-Test™, mTNF-α ELISA Test Kit, Genzyme,
Spain).
An assay for Nitric Oxide concentration was performed
according to Navarro-Gonzáles et al [20].
The blood was centrifuged at 1500 g for 15 min; plasma
was harvested and stored at -80°C until the hormonal
concentration and biomarkers concentration were meas-
ured.
Total protein concentration was determined by the Lowry
assay (Bio-Rad, Madrid, Spain) for tumour homogenates.
In homogenate TNF α, NO concentrations were expressed
relative to total protein.
Histological analysis was performed on primary NMU
tumours on haematoxylin-eosin stained sections. Flow
cytometry (FACScan, Becton Dickinson) was performed
of rat NMU induced tumours. Flow cytometry was per-
formed on nuclei prepared from 40 μm thick sections
from formalin fixed paraffin tissue by the modified tech-
nique of Hedley et al. and McLemore et al [21,22].
Experimental Design
At 55 days of age, the female rats were divided into the fol-
lowing groups:
1- Healthy Controls (n = 10) without NMU-induction.
2- NMU controls (n = 20) received weekly an injection of
NMU [a set of 2 injections during 2 weeks NMU (5 mg/
100 g weight/rat)] and was observed after carcinogen
administration for tumour development.
3- NMU plus metoclopramide (M) (n = 20) in drinking
water (0.125 mg/L), "at libitum", was observed weekly for
tumour development. The elimination half-life for (M) is
5–6 hours.
4- NMU plus goserelin (n = 40) and the metoclopramide
administration was suspended in this group when tumour
was detected and they were subdivided into 2 groups for
(a) acute and (b)chronic study, respectively:
a) Received goserelin administration "in bolus" (0.25 mg/
ml/rat, i.v.) and killed 2 h after injection.
b) Received goserelin (subcutaneous/daily) during 60
days (0.25 mg/ml/day).
Statistical Analysis
Differences in tumour incidence were demonstrated using
x2 analysis and Yates correction. Inter-group comparisons
were performed by Student t test. Values of p < 0.05 were
considered to be significantly different.
Results
Post administration of NMU in control group, mammary
cancer was detected in 9 of 20 (45%) rats on days 90–120.
Metoclopramide treatment had effect on NMU-induced
tumours, where the incidence was 85%. Latency to the
appearance of first palpable tumour tended to be shorter
in all rats that received metoclopramide. Indeed the aver-
age of tumours was higher than in controls, Table 1.
In NMU-induced tumours plus (M) the size of tumours
observed an increase in growth at 400% on 20th day, com-
pared with the administered goserelin, where the tumours
stop in their development or diminish in size (last one
observed at 60th day, Fig 1.
The histology revealed that all the tumours were adeno-
carcinoma.
Analyses by flow cytometry of nuclear DNA patterns
revealed 100% polyploidy in NMU induced tumours.
According to this study all tumour samples were poly-
ploidy-aneuploid and none of them was diploid type, per-
centage of S = 60%, Mitosis (ratio) = 1.99. DNA Index =
1.50 – 2.00, and with a CV (G0/G1) = 9%. Fig 2.
PRL measurements
In plasma  the mean value of PRL levels was lower in
healthy controls [C] (28.5 ± 0.1 ng/ml, n = 20) than in rats
with NMU tumours [T] (51.3 ± 2.2 ng/ml, n = 20), P <
Table 1: Metoclopramide (M) administration on NMU tumours.
Wistar rats Induction time (days) Incidence (%) Average of tumours
Control NMU 90 – 120 45% 0.5 t/rat
NMU + M 55 85% 1.4 t/rat
NMU = N-nitroso-N-methylurea. M = metoclopramide. t = tumour. The tumour induction time, tumour incidence and average of tumours were 
increased in rats with metoclopramide administration.Journal of Carcinogenesis 2007, 6:18 http://www.carcinogenesis.com/content/6/1/18
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0.01. During metoclopramide (M) administration the
PRL basal mean levels were 125.6 ± 8.5 ng/ml, n = 20 in
healthy controls, Fig 3.
The PRL plasma mean levels of NMU tumour rats [T],
were higher than in tumour homogenates [TH] (corre-
sponding to the same group of rats and extraction time)
5.8 ± 1.2 ng/ml (n = 20); these results were statistically sig-
nificant (P < 0.0005).
The PRL plasma levels decreased in NMU rats when they
were treated with goserelin. During acute administration
the time course was, basal: 51.3 ± 2.2 ng/ml (n = 20); 30
min 26.2 ± 6.5 ng/ml (n = 20), P < 0.001; 60 min 17.5 ±
13.5 ng/ml (n = 20), P < 0.0125; and at 90 min: 12.2 ± 4.2
ng/ml (n = 20), P < 0.0005.
During chronic administration of goserelin the mean PRL
levels were similar to those in healthy control rats: 49.0 ±
23.4 ng/ml (n = 20) P = 0.40, Fig 4.
In tumour homogenate [TH] there was no statistically
significant variations of PRL mean levels during acute
administration of goserelin neither post chronically
treated: Basal 5.8 ± 1.2 ng/ml (n = 20); 30 min 6.9 ± 0.1
ng/ml (n = 20), P = 0.20; 60 min 5.6 ± 0.3 ng/ml (n = 20);
at 90 min 6.8 ± 0.2 ng/ml (n = 20), P = 0.35. At 60 days
treatment the mean value was 5.9 ± 0.1 ng/ml (P = 0.35).
TNF alpha measurements
TNFα expression during time course of acute administra-
tion of goserelin observed inhibition in plasma. The
mean values were: Basal 178.7 ± 11.6 pg/ml (n = 20); at
30 min 150.0 ± 15.0 pg/ml (n = 20), P = 0.10; at 60 min
145.2 ± 2.5 pg/ml (n = 20), P < 0.05; and at 90 min. 135.0
± 5.0 (n = 20), P < 0.05; Fig 5.
Flow cytometry analyses of NMU induced mammary  tumours Figure 2
Flow cytometry analyses of NMU induced mammary 
tumours. The dot plot images (top) and histogram (bottom) 
of the NMU-induced adenocarcinoma sample. They 
observed polyploidy distribution in all samples.
Tumours evolution post-NMU administration (0–60 days)  post-first measurement (= 100% as initial size)-: - - NMU  control rats without treatment -- NMU tumours treated  with metoclopramide Figure 1
Tumours evolution post-NMU administration (0–60 days) 
post-first measurement (= 100% as initial size)-: - - NMU 
control rats without treatment -- NMU tumours treated 
with metoclopramide. - - NMU tumours treated with goser-
elin.
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The inhibition of TNF α expression was observed during
post-chronic treatment with goserelin: 132.1 ± 52.2 pg/
ml, n = 20 (P < 0.0125).
In  tumour homogenates mean basal values of TNFα
were: 255.0 ± 30.0 pg/mg of protein (n = 20), at 30 min
210.0 ± 12.5 pg/mg of protein (n = 18), P = 0.20; at 60
min 200.0 ± 15.0 pg/mg of protein (n = 18), P < 0.05; and
at 90 min 210.0 ± 15.0 pg/mg of protein (n = 18), P =
0.10.
At 60 days of goserelin treatment, the TNFα expression
observed a statistically significant inhibition when com-
pared with the basal values, 255.0 ± 30.5 vs. 159.0 ± 5.2
pg/mg of protein (n = 18), P < 0.0125, Fig 6.
Nitric Oxide measurement
In female Wistar rats without NMU induced tumour, the
basal mean NO concentration in plasma was 31.5 ± 9.5
μg/μl, n = 20. The mean NO concentrations were higher
in plasma of female Wistar rats with NMU induced
tumours than basal healthy controls (59.6 ± 5.5 μg/μl n =
20, P < 0.001). In plasma inhibition of NO expression
during time course of acute administration of goserelin
has been observed but these differences were not statisti-
cally significant. Basal mean values were: 59.6 ± 5.5 μg/μl
(n = 20), 30 min 56.7 ± 17.8 μg/μl (n = 20), P = 0.10; at
60 min 64.0 ± 17.9 μg/μl (n = 20) P = 0.15 and at 90 min
52.2 ± 7.5 μg/μl (n = 20) P = 0.25. Lack of inhibition of
NO expression by goserelin was observed during chronic
treatment 46.0 ± 19.9 μg/μl, n = 20 (P = 0.25) when com-
pared with NMU induced basal values, Fig 7.
The NO concentration was inhibited by goserelin acute
treatment in tumour homogenate. The mean basal con-
centration was: 205.9 ± 42.3 μg/μg of protein (n = 20), at
30 min 134.0 ± 17.9 μg/μg of protein (n = 20) P = 0.05, at
60 min: 118.0 ± 22.9 μg/μg of protein (n = 20), P < 0.05,
Time course of TNF α expression in plasma during acute  administration of goserelin Figure 5
Time course of TNF α expression in plasma during acute 
administration of goserelin. The values observed maximal 
inhibition at 90 min from basal values; each point represents 
the mean ± SEM.
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Immunoreactive plasma PRL means levels Figure 3
Immunoreactive plasma PRL means levels. In healthy controls 
(C) without NMU-induced tumours were lower than rats 
with NMU-induced tumours (T), and lower than with meto-
clopramide treatment (M). (Mean ± SEM).
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The plasma PRL time course during goserelin administration Figure 4
The plasma PRL time course during goserelin administration. 
In the NMU induced mammary tumours the values observed 
maximal inhibition at 90 minutes (P < 0.005). PRL value in 
chronically treated rats with goserelin was similar to basal (B) 
value; each point represents the mean ± SEM.
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and at 90 min. 82.3 ± 9.9 μg/μg of protein (n = 20), P <
0.01.
In chronically administered goserelin (at 60 day) the NO
values lowered to 72.4 ± 9.9 μg/μg of protein and when
compared with basal NO values statistically significant
differences was observed between them (P < 0.005), Fig 8.
Discussion
The MNU breast cancer model induced in rats is used for
the study of carcinogenesis in mammary cancer, prostate,
pancreas, etc. This model is very similar to human neo-
plastic disease [23]. The developmental stage of mam-
mary gland at the time of exposure of the gland to NMU
has an important effect of the gland to carcinogenesis [1].
A great variability of various mouse and rat strains for sen-
sitivity on mammary tumours with chemical initiating
agents was studied and considered that their results sup-
port the need to use more then one rat strain for the initi-
ation of mammary carcinogenesis, due to "very low"-
sensitivity for the NMU tumour development in Wistar-
Han rats [24]. Nevertheless, in Wistar rats the incidence of
tumours per rat and percentage of rats with NMU tumours
was lower than observed in Sprague-Dawley rats as
observed in a previous study. In our experiments we
administered intra-peritoneal carcinogen at twice and in
both studies the rats received metoclopramide daily, as
inductor of PRL release and, as has been demonstrated
PRL acts as positive growth factor in mammary tumour
development suggesting that the hormonal mileu around
the time of carcinogen exposure affects not only the inci-
dence and phenotype of mammary transformants but also
the molecular events associated with mammary carcino-
genesis [3,7,25]. Experimental studies proposed that PRL
could act as a local growth factor and may stimulate the
proliferation of mammary NMU-induced tumours.
[7,10,26].
Our study demonstrated that metoclopramide (as
dopaminergic antagonist) has a very high capacity to
induce hyperprolactinemia in rat, indeed the tumour
growth accelerated during the observation period and this
effect could be influenced or stimulated by PRL release.
Concentration of NO in NMU-induced tumour homogenate  during administration of goserelin (time course) Figure 8
Concentration of NO in NMU-induced tumour homogenate 
during administration of goserelin (time course). The maxi-
mal inhibition of NO was at 90 min (*P < 0.01) and remained 
at 60 days (** P < 0.005), each point represents the mean ± 
SEM.
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Effect of goserelin on TNF α concentration in tumour  homogenate Figure 6
Effect of goserelin on TNF α concentration in tumour 
homogenate. At 60 days of LH-RH treatment, the mean value 
of TNF α was lower than basal value (P < 0.0125) (mean ± 
SEM).
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Expression of NO in plasma in the NMU-induced mammary  tumours Figure 7
Expression of NO in plasma in the NMU-induced mammary 
tumours. Healthy control without tumours (C) versus basal 
(b) NMU induced rats *P < 0.001 (Values expressed as mean 
± SEM). During the time course for NO expression acute 
and chronic administration of goserelin, between them the 
differences were not statistically significant.
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These results are in agreement with different previous
experimental and clinical studies on PRL-induced prolif-
eration. [9,27-33]. Thus sulpiride a selective dopamine
D2 antagonist has been documented in a clinical study
the administration of LH-RH inhibits sulpiride-induced
hyperprolactinemia [34].
The histological study of our tumours revealed adenocar-
cinoma type, similar to observed in human breast cancer.
Flow cytometric S-phase fraction contributes to diagnosis
of tumours. At present to our knowledge, only flow cyto-
metric analyses were performed in NMU-induced solid
tumours in rat prostate [35]. Monakov et al [36] observed
chromosomal damages and polyploidy and hiperpoly-
ploid in somatic cells after the NMU administration and
considered that they can serve as a prognostic factor of car-
cinogenesis. Our study is the first communication about
the flow cytometry analysis of the NMU-induced tumours
in female rats and it showed polyploidy (aneuploid) in all
the tumour samples. These results contributed to discrim-
inate from possible benign-induced tumours since benign
tumours would be diploid type.
Initially an acute administration of LH-RH agonist
induces a release of LH and FSH. However, continuous
and chronic administration produces an inhibition of the
hypophyseal-gonadal-axis though the process of "down
regulation" of pituitary receptors for LH-RH. Furthermore
the expression on LH-RH receptor gene was established in
tumours [37]. In our study the tumour growth was inhib-
ited by chronically administration of goserelin and an
important tumour regression was observed at 60 days of
treatment. During chronic administration of goserelin the
mean PRL levels were similar to that in healthy control
rats, in this way previous metoclopramide-induced hyper-
prolactinemia and by tumour presence, PRL expression
was inhibited. During our study we observed an increase
of plasmatic TNF α in rats with NMU-induced and estra-
diol dependent tumours when compared to controls
without NMU-induced tumours. Moreover, it is well
known that a variety of chemical carcinogens can
adversely affect the immune system and influence tumour
evolution and exert toxic effect on lymphoid organs, thus
possibly affecting the production of cytokines at the initi-
ation of carcinogenesis. This increment was inhibited by
LH-RH analogues treatment and according to Tagami et
al. may act by inhibition of estrogens production, because
estrogens are also responsible of COX-2 induction, the
same way as c-fos, IL-1 and TNF alpha [38].
It is well known that NO is a free radical that mediates a
variety of cell functions. The plasmatic NO expression of
our study showed a statistically significant increase of NO
concentration in rats with NMU-induced tumours when
compared to controls, which was observed in basal condi-
tions. These results suggest that NO can stimulate tumour
growth. Additionally, TNFα induces iNOS and NO pro-
duction and could mediate tumour promoter-induced
transformation.
In this study we have examined PRL, TNF alpha and NO
levels in plasma and in tumour homogenates during gos-
erelin administration and, similar behaviour was
observed. PRL levels in homogenate presented no statisti-
cal significant differences. It could be due to the initial low
values in homogenate or because the sensitivity of the
assay was insufficient.
It is well known that NO levels in cancer cells contribute
to tumour angiogenesis and during acute administration
of goserelin it did not completely inhibit this increase. At
present, the practical importance of these values or rele-
vance with respect to predicting the disease course is not
clear.
This study demonstrates firstly the role "in vivo" of meto-
clopramide on tumour growth and secondly for goserelin
in NMU-induced mammary tumours in which inhibitory
effects were observed on growth as well as with significant
tumour regression, besides it also exerted inhibitory
effects on plasmatic and tissular PRL, TNFα and ON
expression. In summary, these findings could reveal a pos-
sible new inhibitory pathway in the tumour development
regulation by LH-RH analogues.
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